BioCentury
ARTICLE | Finance

Liberating Labrys

Teva provides Labrys investors front-loaded exit on migraine play

June 9, 2014 7:00 AM UTC

Less than two years after pumping $31 million into migraine play Labrys Biologics Inc., investors will see a front-loaded return in a takeout by Teva Pharmaceutical Industries Ltd. (NYSE:TEVA).

Teva is acquiring Labrys for $200 million in cash up front, plus up to $625 million in developmental milestones...